AU2005327506B2 - Antisense modulation of integrin alpha4 expression - Google Patents

Antisense modulation of integrin alpha4 expression Download PDF

Info

Publication number
AU2005327506B2
AU2005327506B2 AU2005327506A AU2005327506A AU2005327506B2 AU 2005327506 B2 AU2005327506 B2 AU 2005327506B2 AU 2005327506 A AU2005327506 A AU 2005327506A AU 2005327506 A AU2005327506 A AU 2005327506A AU 2005327506 B2 AU2005327506 B2 AU 2005327506B2
Authority
AU
Australia
Prior art keywords
animal
administered
composition
antisense compound
integrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005327506A
Other languages
English (en)
Other versions
AU2005327506A1 (en
Inventor
C. Frank Bennett
Jeffrey R. Crosby
Kenneth W. Dobie
Susan Gregory
James G. Karras
George Tachas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Percheron Therapeutics Ltd
Original Assignee
Antisense Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antisense Therapeutics Ltd filed Critical Antisense Therapeutics Ltd
Publication of AU2005327506A1 publication Critical patent/AU2005327506A1/en
Application granted granted Critical
Publication of AU2005327506B2 publication Critical patent/AU2005327506B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2005327506A 2004-10-20 2005-10-20 Antisense modulation of integrin alpha4 expression Ceased AU2005327506B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62079204P 2004-10-20 2004-10-20
US60/620,792 2004-10-20
US64882005P 2005-01-31 2005-01-31
US60/648,820 2005-01-31
PCT/AU2005/001634 WO2006086821A1 (en) 2004-10-20 2005-10-20 ANTISENS MODULATION OF INTEGRIN α4 EXPRESSION

Publications (2)

Publication Number Publication Date
AU2005327506A1 AU2005327506A1 (en) 2006-08-24
AU2005327506B2 true AU2005327506B2 (en) 2010-07-08

Family

ID=36916094

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005327506A Ceased AU2005327506B2 (en) 2004-10-20 2005-10-20 Antisense modulation of integrin alpha4 expression

Country Status (9)

Country Link
US (1) US8765700B2 (enExample)
EP (1) EP1809302B1 (enExample)
JP (1) JP2008516991A (enExample)
AU (1) AU2005327506B2 (enExample)
CA (1) CA2584614A1 (enExample)
DK (1) DK1809302T3 (enExample)
ES (1) ES2392449T3 (enExample)
NZ (1) NZ554277A (enExample)
WO (1) WO2006086821A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2699891T3 (es) * 2008-06-23 2019-02-13 Antisense Therapeutics Ltd Métodos para tratar la esclerosis múltiple usando oligonucleótidos antisentido
US20120258093A1 (en) 2009-08-20 2012-10-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
EP2616081A4 (en) * 2010-09-17 2014-01-01 Antisense Therapeutics Ltd METHOD FOR MOBILIZING STEM AND / OR PROGENITOR CELLS
WO2013142514A1 (en) * 2012-03-19 2013-09-26 Isis Pharmaceuticals, Inc. Methods and compositions for modulating alpha-1-antitrypsin expression
CN104272317B (zh) * 2012-06-01 2017-09-15 英特尔公司 在更安全的执行环境中标识并执行多个指令的子集
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
AU2016259971B2 (en) * 2015-05-11 2021-12-09 ProGenis Pty Ltd Multiple sclerosis treatment
ES2938883T3 (es) * 2015-11-05 2023-04-17 Los Angeles Childrens Hospital Oligo antisentido para su uso en el tratamiento de la leucemia mieloide aguda
TW202436621A (zh) 2017-01-10 2024-09-16 美商愛羅海德製藥公司 α-1抗胰蛋白酶 (AAT) RNAi 藥劑、包含AAT RNAi 藥劑之組合物及使用方法
WO2019210347A1 (en) 2018-05-04 2019-11-07 Antisense Therapeutics Ltd Therapeutic uses and methods
EP3980540A4 (en) * 2019-06-06 2023-11-01 Arrowhead Pharmaceuticals, Inc. METHOD FOR TREATING ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
WO2023039643A1 (en) * 2021-09-20 2023-03-23 Antisense Therapeutics Ltd Methods and kits therefor
AU2023375420A1 (en) * 2022-11-09 2025-06-19 Gmp Biotechnology Limited Anti-cancer agents
AU2023375416A1 (en) * 2022-11-09 2025-06-19 Gmp Biotechnology Limited Compositions and methods for cns diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968826A (en) * 1998-10-05 1999-10-19 Isis Pharmaceuticals Inc. Antisense inhibition of integrin α4 expression
WO2000039292A2 (de) * 1998-12-29 2000-07-06 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Antisense-oligonukleotid zur hemmung der expression des adhäsionsmoleküls very late antigen 4 (vla-4) in menschlichen zellen

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4309406A (en) 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4309404A (en) 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4556552A (en) 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
US4704295A (en) 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
DE3788914T2 (de) 1986-09-08 1994-08-25 Ajinomoto Kk Verbindungen zur Spaltung von RNS an eine spezifische Position, Oligomere, verwendet bei der Herstellung dieser Verbindungen und Ausgangsprodukte für die Synthese dieser Oligomere.
ATE151467T1 (de) 1987-11-30 1997-04-15 Univ Iowa Res Found Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene
US5403711A (en) 1987-11-30 1995-04-04 University Of Iowa Research Foundation Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
DE69034150T2 (de) 1989-10-24 2005-08-25 Isis Pharmaceuticals, Inc., Carlsbad 2'-Modifizierte Oligonukleotide
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5623065A (en) 1990-08-13 1997-04-22 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
US5955589A (en) 1991-12-24 1999-09-21 Isis Pharmaceuticals Inc. Gapped 2' modified oligonucleotides
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5859221A (en) 1990-01-11 1999-01-12 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5220007A (en) 1990-02-15 1993-06-15 The Worcester Foundation For Experimental Biology Method of site-specific alteration of RNA and production of encoded polypeptides
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
DK0455905T3 (da) 1990-05-11 1998-12-07 Microprobe Corp Dipsticks til nukleinsyrehybridiseringsassays og fremgangsmåde til kovalent immobilisering af oligonukleotider
EP0538194B1 (de) 1991-10-17 1997-06-04 Novartis AG Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
US5700922A (en) 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
FR2687679B1 (fr) 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
FR2692265B1 (fr) 1992-05-25 1996-11-08 Centre Nat Rech Scient Composes biologiquement actifs de type phosphotriesters.
EP0577558A2 (de) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
ES2107205T3 (es) 1993-03-30 1997-11-16 Sanofi Sa Analogos de nucleosidos aciclicos y secuencias oligonucleotidas que los contienen.
DE4311944A1 (de) 1993-04-10 1994-10-13 Degussa Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen
FR2705099B1 (fr) 1993-05-12 1995-08-04 Centre Nat Rech Scient Oligonucléotides phosphorothioates triesters et procédé de préparation.
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
JP3585238B2 (ja) 1993-12-09 2004-11-04 トーマス ジェファーソン ユニバーシティー 真核細胞における部位特異的突然変異誘発のための化合物および方法
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5696248A (en) 1994-06-15 1997-12-09 Hoechst Aktiengesellschaft 3'-modified oligonucleotide derivatives
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5652356A (en) 1995-08-17 1997-07-29 Hybridon, Inc. Inverted chimeric and hybrid oligonucleotides
US6127533A (en) 1997-02-14 2000-10-03 Isis Pharmaceuticals, Inc. 2'-O-aminooxy-modified oligonucleotides
US6083923A (en) 1997-10-31 2000-07-04 Isis Pharmaceuticals Inc. Liposomal oligonucleotide compositions for modulating RAS gene expression
CN1330513A (zh) * 1999-04-06 2002-01-09 东卡罗来纳大学 低腺苷反义寡核苷酸、组合物、试剂盒及与支气管紧缩、肺炎、过敏及表面活性剂缺失相关的通气途径疾病的治疗方法
CA2597845A1 (en) * 2005-02-25 2006-08-31 Isis Pharmaceuticals, Inc. Compositions and their uses directed to il-4r alpha

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968826A (en) * 1998-10-05 1999-10-19 Isis Pharmaceuticals Inc. Antisense inhibition of integrin α4 expression
US6258790B1 (en) * 1998-10-05 2001-07-10 Isis Pharmaceuticals, Inc. Antisense modulation of integrin α4 expression
WO2000039292A2 (de) * 1998-12-29 2000-07-06 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Antisense-oligonukleotid zur hemmung der expression des adhäsionsmoleküls very late antigen 4 (vla-4) in menschlichen zellen

Also Published As

Publication number Publication date
ES2392449T3 (es) 2012-12-10
DK1809302T3 (da) 2012-11-26
EP1809302A4 (en) 2010-07-14
EP1809302A1 (en) 2007-07-25
AU2005327506A1 (en) 2006-08-24
US20090029931A1 (en) 2009-01-29
US8765700B2 (en) 2014-07-01
EP1809302B1 (en) 2012-08-22
NZ554277A (en) 2010-09-30
CA2584614A1 (en) 2006-08-24
JP2008516991A (ja) 2008-05-22
WO2006086821A1 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
US7148204B2 (en) Antisense modulation of bcl-x expression
ES2729956T3 (es) Compuestos antisentido dirigidos al factor de crecimiento de tejido conectivo (ctgf) para su uso en un procedimiento de tratamiento de queloides o cicatrices hipertróficas
US6111094A (en) Enhanced antisense modulation of ICAM-1
AU2005327506B2 (en) Antisense modulation of integrin alpha4 expression
JP2002526125A (ja) 腫瘍壊死因子−α（ＴＮＦ−α）発現のアンチセンス・オリゴヌクレオチド調節
JP2015518712A (ja) Ｍｅｃｐ２発現を調節するための組成物及び方法
JP2002539846A (ja) インターロイキン−５シグナルトランスダクションのアンチセンスモジュレーション
JP2015523855A (ja) Ａｐｏａ１及びａｂｃａ１発現を調節するための組成物及び方法
JP4168285B2 (ja) インテグリンα４発現のアンチセンス調節
US6087489A (en) Antisense oligonucleotide modulation of human thymidylate synthase expression
JP7604361B2 (ja) 治療での使用及び方法
WO2002013799A2 (en) Oligonucleotides and other modulators of the nk-1 receptor pathway and therapeutic uses thereof
CA3138945A1 (en) Methods for treating muscular dystrophy using inhibitory oligonucleotides to cd49d
US7393950B2 (en) Antisense oligonucleotides targeted to human CDC45
TW202426642A (zh) 用於減少ｍｅｃｐ２表現之化合物及方法
US8318922B2 (en) Treatment and prevention of hyperproliferative conditions in humans and antisense oligonucleotide inhibition of human replication-initiation proteins
AU2024220263A1 (en) Allele-selective compounds and methods for modulating huntingtin expression
WO2024159266A1 (en) Combination compositions and methods for treatment of muscular dystrophy

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ ANTISENSE MODULATION OF INTEGRIN ALPHA4 EXPRESSION

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired